{"links":{"html":"https://www.erudio.com/reports/gmmg-hd6-nct02495922","json":"https://www.erudio.com/reports/gmmg-hd6-nct02495922.json","markdown":"https://www.erudio.com/reports/gmmg-hd6-nct02495922.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"gmmg-hd6-02495922"}},"request":"https://www.erudio.com/contact?report=gmmg-hd6-02495922"},"offer":{"cited_commentary_sources":20,"verified_hcp_statements":194,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":24,"optional":true,"price_per_verified_person_usd":15,"price_usd":360,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"gmmg-hd6-nct02495922"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=gmmg-hd6-02495922","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/gmmg-hd6-nct02495922","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T18:00:45.857876Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: per-finding counts; the sample findings; the report description."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":1},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: the best of four treatment strategies regarding Progression Free Survival (PFS)"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":1,"title":"Patient-reported outcomes with RVd with or without elotuzumab in newly diagnosed myeloma"},{"claim_count":26,"coverage":"discussed","id":"A2","source_count":6,"title":"Broader elotuzumab role, selective relapse use and access constraints"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":1,"title":"Discordant Elo/KRd evidence and the need for durable outcomes"},{"claim_count":20,"coverage":"discussed","id":"A4","source_count":1,"title":"Post-ASCT maintenance for isolated 1q gain versus amplification"},{"claim_count":11,"coverage":"discussed","id":"A5","source_count":1,"title":"MRD-guided tailoring, treatment burden and de-escalation"},{"claim_count":15,"coverage":"discussed","id":"A6","source_count":1,"title":"Evidence thresholds for maintenance, escalation and surveillance"},{"claim_count":9,"coverage":"discussed","id":"A7","source_count":1,"title":"Maintenance counseling and informed refusal"},{"claim_count":12,"coverage":"discussed","id":"A8","source_count":5,"title":"FISH, clonal hierarchy and prognostic work-up"},{"claim_count":9,"coverage":"discussed","id":"A9","source_count":1,"title":"IRMMa individualized prognosis and modeled treatment variance"},{"claim_count":7,"coverage":"discussed","id":"A10","source_count":5,"title":"Historical treatment access and the value of negative studies"}],"counts":{"cited_sources":26,"claims_by_expression_type":{"comparison":11,"experience":10,"interpretation":51,"opinion":57,"primary_context":16,"question":8,"restatement":23,"uncertainty":15,"unspecified":3},"claims_by_kind":{"objective_result":5,"protocol_statement":6,"publication_statement":60,"source_observation":123},"clinician_statements":98,"evidence_units":175,"findings":11,"people_cited":25,"people_identity_verified":24,"people_total":25,"screened_sources":42,"verified_claims":194},"findings_index":[{"id":"F1","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":3,"views":9},"has_counterview":true,"limitations":2,"links":{"context":1,"support":16},"ma_question":true,"named_voices":7,"passages":13,"sources":7,"sources_by_kind":{"commentary":6,"publication":1}},"title":"Negative frontline findings prompted broader rejection, but a no-role conclusion remains an opinion"},{"id":"F2","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":8,"questions":1,"restated":1,"views":5},"has_counterview":true,"limitations":2,"links":{"context":1,"support":15},"ma_question":true,"named_voices":6,"passages":9,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Selective bridging and access uses qualify broad rejection of elotuzumab"},{"id":"F3","structure":{"claims":12,"claims_by_group":{"comparisons":2,"experience":1,"questions":2,"restated":3,"views":4},"has_counterview":true,"limitations":2,"links":{"context":3,"support":12},"ma_question":true,"named_voices":7,"passages":11,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Response, MRD and durable benefit are kept distinct, including discordant Elo/KRd evidence"},{"id":"F4","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"media":1,"publication":1}},"title":"A null quality-of-life finding is not evidence of equivalent safety"},{"id":"F5","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":3,"passages":8,"sources":7,"sources_by_kind":{"commentary":6,"publication":1}},"title":"Negative efficacy did not erase the perceived value of the design or historical treatment access"},{"id":"F6","structure":{"claims":22,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":5,"views":16},"has_counterview":true,"limitations":3,"links":{"context":2,"support":22},"ma_question":true,"named_voices":9,"passages":21,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Post-ASCT maintenance debate turns on isolated 1q gain versus amplification"},{"id":"F7","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":1,"views":8},"has_counterview":true,"limitations":2,"links":{"context":2,"support":12},"ma_question":true,"named_voices":7,"passages":13,"sources":1,"sources_by_kind":{"commentary":1}},"title":"MRD-guided tailoring is attractive to some, but treatment burden and stopping rules remain uncertain"},{"id":"F8","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":2,"views":9},"has_counterview":true,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":5,"passages":16,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Keeping established maintenance and adding drugs require different evidence arguments"},{"id":"F9","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":9},"ma_question":true,"named_voices":3,"passages":8,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Maintenance counseling includes evidentiary conviction and informed refusal, not only toxicity"},{"id":"F10","structure":{"claims":13,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":5,"views":6},"has_counterview":true,"limitations":3,"links":{"context":5,"support":13},"ma_question":true,"named_voices":5,"passages":6,"sources":6,"sources_by_kind":{"commentary":5,"publication":1}},"title":"Clonal hierarchy adds nuance to FISH-based risk, with validation still required"},{"id":"F11","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":7,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":17},"ma_question":true,"named_voices":1,"passages":17,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"IRMMa offers individualized research predictions, not validated instructions to omit or intensify treatment"}],"medical_affairs_question":"How should Medical Affairs distinguish lack of added frontline benefit from regimen-specific uncertainty, selective access uses and evidence-supported maintenance personalization?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Negative frontline findings versus a drug-wide no-role conclusion"},{"id":"section-2","level":2,"title":"Selective later-line use: access, bridging and patient preference"},{"id":"section-3","level":2,"title":"Endpoint and backbone specificity: why the Elo/KRd exception remains open"},{"id":"section-4","level":2,"title":"Quality of life: no significant between-group impact, improvement within groups"},{"id":"section-5","level":2,"title":"Trial value despite a negative intervention result"},{"id":"section-6","level":2,"title":"Isolated 1q gain, amplification and post-ASCT maintenance intensity"},{"id":"section-7","level":2,"title":"MRD, treatment burden and uncertain de-escalation"},{"id":"section-8","level":2,"title":"Evidence standards: maintenance, escalation and surveillance are different questions"},{"id":"section-9","level":2,"title":"Counseling: recommendation strength and informed refusal"},{"id":"section-10","level":2,"title":"FISH and clonal hierarchy: useful work-up, exploratory risk refinements"},{"id":"section-11","level":2,"title":"IRMMa: research prediction and treatment variance, not an omission rule"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: the best of four treatment strategies regarding Progression Free Survival (PFS)"},{"findings":[{"id":"F3","shared_claims":3}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":3}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T18:00:45.857876Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T18:12:26Z","record_hash":"afb578ad25a911d5c8e1b71dd6d6a4bb9f22c4e10282342e99613a5db5acdec7","release_hash":"0ccd984edb5eb053cf3ad73dc53d98f4adc51e08fc72efe8741db8c5fe02811a","report_id":"erudio-nct02495922","run_id":"35fad8cb-67f4-4740-9ba2-f2a8611df2e0","schema_version":"5.0","slug":"gmmg-hd6-02495922","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"GMMG-HD6 asks whether adding elotuzumab to RVd-based therapy and lenalidomide maintenance improves disease control in people with newly diagnosed myeloma who are eligible for transplantation. Commentary comes from X and LinkedIn posts, a podcast and YouTube interviews, with a physician among the speakers. The discussion turns on elotuzumab’s contested role beyond frontline treatment, whether response and MRD signals translate into durable benefit, and the different evidence arguments for continuing versus intensifying post-transplant maintenance.","meta_description":"42 sources screened · 194 verified statements (98 from clinicians verified by NPI or staff page) from 26 sources · 11 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-9d63f49982854b2ddbef","claim-08dae241714d62314004","claim-d09a44e13f458a42ea52"],"id":"F3","paraphrase":"In an X exchange about GMMG-HD6, questions address how to reconcile findings from a separate Elo/KRd–KRd study and what its progression-free and overall survival results show.","source_channel":"x_thread","source_date":"2024-02-01","title":"Response, MRD and durable benefit are kept distinct, including discordant Elo/KRd evidence"},{"cited_claim_ids":["claim-a52aa91cddad2a3b56cd","claim-74740ddebd8ea6551f86"],"id":"F8","paraphrase":"An X thread raises methodological questions about the evidence supporting maintenance decisions. The discussion provides context for GMMG-HD6’s maintenance backbone, not trial-specific comparative results.","source_channel":"x_thread","source_date":"2021-04-20","title":"Keeping established maintenance and adding drugs require different evidence arguments"}]},"publication":{"approved_at":"2026-10-30T18:12:26Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-30T23:43:25Z","summary":"Corrected to match the delivered report: per-finding counts; the sample findings; the report description."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":42},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","81 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion. The report cannot estimate prevalence or consensus.","Reposts, quoted posts and podcast/video versions may repeat the same view and are not independent endorsements.","Some potentially relevant passages were not fully assessed, and an additional view in the late-relapse video could not be included with sufficient supporting detail. Further qualifications or practical concerns may be missing.","The podcast version does not identify who spoke the elotuzumab passage. Its statements remain unattributed despite a named speaker in the video version.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A speaker's involvement in GMMG-HD6 is described by the source. Those views should not be counted as an independent external assessment of the trial.","The maintenance, MRD, related FISH and quality-of-life discussions that do not name GMMG-HD6 are contextual to its clinical question, not additional trial results.","The Elo/KRd MRD figures, FORTE interpretations, SWOG S1211 comparison, Perseus comparison and IRMMa analyses must retain their own study, endpoint and setting.","A protocol publication was available, but no protocol document was listed in the registry. Prospective expectations in the protocol are not observed outcomes.","Not all identified regulatory material was reviewed. Historical treatment-line and insurer experiences do not establish all current access requirements.","The absence of substantive clinician commentary on the trial's grade 3-or-higher toxicity comparison does not establish a favorable safety interpretation."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":6,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":20,"context":2,"methods":1,"results":3},"count":26,"evidence_window":{"end":"2026-08-03","start":"2020-06-12"},"retrieval_snapshot":"2026-10-30T16:14:43.178413Z","timeline":[{"count":2,"week":"2020-W24"},{"count":1,"week":"2021-W16"},{"count":1,"week":"2021-W46"},{"count":2,"week":"2021-W49"},{"count":1,"week":"2024-W02"},{"count":1,"week":"2024-W03"},{"count":4,"week":"2024-W05"},{"count":1,"week":"2024-W06"},{"count":5,"week":"2024-W49"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W04"},{"count":2,"week":"2026-W32"}],"undated_sources":6},"quote_policies":[{"id":"clinicaltrials:NCT02495922:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02495922:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:27195659","quote_policy":"short_quote_link_out"},{"id":"pubmed:31138244","quote_policy":"short_quote_link_out"},{"id":"pubmed:37990162","quote_policy":"short_quote_link_out"},{"id":"pubmed:38062124","quote_policy":"short_quote_link_out"},{"id":"pubmed:38194610","quote_policy":"short_quote_link_out"},{"id":"pubmed:38302221","quote_policy":"short_quote_link_out"},{"id":"openfda:80686b7e-f6f4-4154-b5c0-c846425e2d91:20220322","quote_policy":"short_quote_link_out"},{"id":"openfda:1b2716cf-24b4-4157-a218-58ede63917bd:20260527","quote_policy":"short_quote_link_out"},{"id":"openfda:b605b541-4bfd-db3e-9710-11c27f6dee6c:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7158545863621926913","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7161464218691592193","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8a298e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1129703160254214145:d4de5372-77ef-417f-83dd-00d45bbb484f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1271457374780481536:2e7a5d68-2fe5-4a29-a8d2-8490a1246836","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1271546882158968833:82d890f8-a081-47b1-9939-42c8c0ecd266","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1271673449803628544:52500dc0-3018-48ed-9563-71c37c771174","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1384533218507038722:e4599bb0-123c-4bac-8269-927cbca142f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1462470762103775237:808a4ec4-cb24-4cd1-a410-3ef472fb0849","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1469307870571384842:62d5b282-c1e8-4a71-9020-aa6a6c8959c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1470096457978023954:f156e37b-d2f5-410a-8586-9d5d032d1cd4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1470096520179560449:f9cff05c-b7f2-4f75-b6ef-39c06ebfe5c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1470096622713462787:efe48a78-abd0-40d6-8165-0f78ac01db6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1727297668047859763:b6434f01-fa2b-4449-b741-bae4a15135fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1744925362432176414:677cde2d-1c28-43bb-a449-8ad6048f1898","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1745046483982819680:cf96ca9a-6dfb-4e3e-89d1-37d47ebf062f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1745078215868350890:4ca2e466-8c8c-4dfa-8526-3d2e885062fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1745087203812741126:a94d3317-f1b8-4b74-a67c-84e5deceef7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1747355499094302961:2e2c88bf-4991-4f68-b4df-f8d635e41162","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1752781983908766194:911edd9f-db27-457c-9df1-4a4985d8be86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1752783008086569212:b107633a-7725-40be-9637-c06fd3c8fe4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1752790086666834345:9617876a-b8df-49f4-9ef3-0dd22b6851f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1752850052517675267:7bcf991e-7806-4dc6-bd78-bce516777abc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1753078635005935682:d1bb9360-ed16-4e83-8b62-ab7c568e0e6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1753600151699267961:d81ce69c-af02-4cf0-98e5-49446acce854","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754267003286630751:7e21505f-a538-4418-9cfa-1fe06b50bfdd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1757036540750881012:99ff1769-fb5f-4272-9f9f-e62616ef6dce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1782763417410904087:3201401a-6774-43f6-ab09-2c8432986880","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1788177032204959876:a4bc3e2c-5bcc-4056-92dc-fdd9d879ddde","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1853917039271817427:edbe7b8e-0b15-4597-acc2-e68792719011","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1854252388544344088:66033629-841f-4110-814e-d41f2c2ccb30","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865469593323811130:73e99345-c39d-494b-9bb6-f21c853322c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865469601511080317:a641d756-3553-415d-ab3d-b3e85c27fdfb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865469727101087788:16fdd53e-96b7-4c9e-8362-b3763455d816","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865469937420251621:164f47e3-bca1-4349-b185-656c94827f48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865470525767844325:a5c24c83-a522-484f-87ea-470c4402d849","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865566303638933682:60961dd1-6f46-46a0-ab6f-6590ed8546c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1872245044897624479:dddcd705-be85-48bd-8d2e-bf88cd99542c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1892333696222400819:bd3d65d8-095e-4b36-97ea-25103ec55b73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066521307450167688:de237367-4261-4d92-8afe-34c6ae4b8542","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:STKOc8NYqfE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:pDfnyBDz0sA","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":37,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":42},"count":42,"evidence_window":{"end":"2026-08-03","start":"2019-05-18"},"retrieval_snapshot":"2026-10-30T16:14:43.178413Z","timeline":[{"count":1,"week":"2019-W20"},{"count":3,"week":"2020-W24"},{"count":1,"week":"2021-W16"},{"count":1,"week":"2021-W46"},{"count":4,"week":"2021-W49"},{"count":1,"week":"2023-W47"},{"count":4,"week":"2024-W02"},{"count":2,"week":"2024-W03"},{"count":8,"week":"2024-W05"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W19"},{"count":2,"week":"2024-W45"},{"count":6,"week":"2024-W49"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2024-W52"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W26"},{"count":2,"week":"2026-W32"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: elotuzumab","status":"unmapped"},{"brand_names":["Revlimid"],"label":"lenalidomide","slug":"lenalidomide"},{"brand_names":["Velcade"],"label":"bortezomib","slug":"bortezomib"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"GMMG-HD6","aliases":["GMMG-HD6","A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma","A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma"],"brief_title":"A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Multiple Myeloma"],"display_condition":"newly diagnosed multiple myeloma","display_interventions":[["elotuzumab"]],"enrollment":{"count":564,"type":"ACTUAL"},"interventions":[{"name":"elotuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Lenalidomide","synonyms":["Revlimid"],"type":"DRUG"},{"name":"Bortezomib","synonyms":["Velcade"],"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT02495922","official_title":"A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2021-06-24","type":"ACTUAL"},"primary_endpoints":[{"description":"response evaluation","measure":"the best of four treatment strategies regarding Progression Free Survival (PFS)","timeFrame":"time from randomization to progression or death from any cause whichever comes first, censored after two years of maintenance therapy (i.e. approx. after 36 months after randomisation)"}],"registered_date":{"date":"2015-07-13","type":"ESTIMATED"},"registry_last_updated":"2021-09-10","registry_url":"https://clinicaltrials.gov/study/NCT02495922","short_name":"GMMG-HD6","short_name_basis":"registry_acronym","sponsor":"University of Heidelberg Medical Center","start_date":{"date":"2015-06"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"GMMG HD6","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}